
Latest in FDA
GSK lung cancer drug wins US approval, validating Nuvalent acquisition strategy
FDA approval for GSK's lung cancer drug neladalkib strengthens its oncology portfolio and underscores the value of strategic biotech acquisitions.
EUBizNews EditorialEUBizNews Editorial••5 min read
